source
- Biogen CEO says early-stage R&D now a priority after record five INDs this yearBiogen's chief executive Chris Viehbacher told analysts that the company has shifted its strategy toward early-stage research and development. He highlighted that Biogen has filed five investigati…
- Former Novo and Sanofi staff describe mixed layoff experiences, citing severance benefits and poor communicationThree former employees of large pharmaceutical companies, including Novo and Sanofi, spoke to BioSpace about how they were let go. Their accounts form part of a broader survey that collects layoff…